Evidence map›Paper›PMID 26512116›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells.

Huimin Zhang, Haiquan Lu, Lisha Xiang, John W Bullen, Chuanzhao Zhang, Debangshu Samanta, Daniele M Gilkes, Jianjun He, Gregg L Semenza

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 253 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
253citing papers in PubMed, 1 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

253 citing papers in PubMed, 1 synthesis or guideline pooled it, 425 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. CD47 and FOXP3Cancers · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Emerging Nanoplatforms are Effective Against Tumor Hypoxia.International journal of nanomedicine · 2026
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

193 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Huimin ZhangDepartment of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, China; Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;
Haiquan LuInstitute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;
Lisha XiangInstitute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;
John W BullenInstitute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;
Chuanzhao ZhangInstitute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;
Debangshu SamantaInstitute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;
Daniele M GilkesDepartment of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;
Jianjun HeDepartment of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, China;
Gregg L SemenzaInstitute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; Department of Radiation Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, MD 21205 gsemenza@jhmi.edu.
Johns Hopkins Medicine · USJohns Hopkins University · USFirst Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

The role of the hypoxic ECM on integrin-induced breast cancer metastasisR00CA181352 · NCI · JOHNS HOPKINS UNIVERSITY · PI GILKES, DANIELE MARIE · 2015 to 2017
$747k
NCI NIH HHS R00 CA181352
6 · The paper itself

Abstract

Increased expression of CD47 has been reported to enable cancer cells to evade phagocytosis by macrophages and to promote the cancer stem cell phenotype, but the molecular mechanisms regulating CD47 expression have not been determined. Here we report that hypoxia-inducible factor 1 (HIF-1) directly activates transcription of the CD47 gene in hypoxic breast cancer cells. Knockdown of HIF activity or CD47 expression increased the phagocytosis of breast cancer cells by bone marrow-derived macrophages. CD47 expression was increased in mammosphere cultures, which are enriched for cancer stem cells, and CD47 deficiency led to cancer stem cell depletion. Analysis of datasets derived from thousands of patients with breast cancer revealed that CD47 expression was correlated with HIF target gene expression and with patient mortality. Thus, CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1.

Indexed as

Analysis of VarianceBreast NeoplasmsCD47 AntigenCell Line, TumorChromatin ImmunoprecipitationDNA PrimersFemaleGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1ImmunoblottingLuciferasesNeoplastic Stem CellsPhagocytosisReal-Time Polymerase Chain ReactionRNA, Small InterferingCD47 AntigenCD47 protein, humanDNA PrimersHypoxia-Inducible Factor 1LuciferasesRNA, Small Interferingantitumor immunity“don’t eat me” signalimmune evasiontumor-initiating cellstumor microenvironment

Identifiers

PMID26512116
PMCPMC4653179
OpenAlexW1853160207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.